🔎 Trials Near Me

Home › Liposarcoma › Missouri

Pag-aaral pangklinika para sa Liposarcoma sa Missouri

5 pag-aaral para sa Liposarcoma ang naghahanap ng mga kalahok sa mga site sa Missouri.

Mga Lungsod sa Missouri

Opisyal na teksto ng pag-aaral (English)

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  • Siteman Cancer Center at West County Hospital, Creve Coeur
  • Washington University School of Medicine, St Louis
  • Siteman Cancer Center-South County, St Louis
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06422806

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

  • Siteman Cancer Center-West County, Creve Coeur
  • Washington University School of Medicine - Siteman Cancer Center, St Louis
  • Siteman Cancer Center-South Country, St Louis
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT04031677

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

  • Washington University School of Medicine, St Louis
  • Siteman Cancer Center-South County, St Louis
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT05711615

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Children's Mercy Hospitals and Clinics, Kansas City
  • Cardinal Glennon Children's Medical Center, St Louis
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06541262

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • Washington University Medical Center, St Louis
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06239272

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.